Sentante

Sentante operates at the intersection of medical devices, robotics, endovascular care, and AI-enabled clinical workflows. Its product is differentiated by a device-agnostic approach: physicians can manipulate standard guidewires and catheter-based devices rather than adopting a fully proprietary instrument ecosystem. The platform combines a remote physician workstation, live imaging, haptic feedback, motion scaling, tremor reduction, and simultaneous control of up to three devices. This positions Sentante against the broader field of robotic vascular intervention companies, but the available comparable-company information does not identify named direct competitors for a reliable company-by-company comparison. Its strongest strategic distinction is the combination of remote operation and procedural data capture. The CE mark announced on May 22, 2026 provides a regulatory foundation for European use, while the Jul 23, 2026 positioning around physical AI signals an attempt to extend beyond mechanical assistance into data-driven intervention support. The main market uncertainties are adoption speed, reimbursement, clinical evidence, and the company’s ability to scale hospital deployment.

Sentante’s trajectory shows a progression from grant-supported development to funded commercialization. The company raised a $56,842 grant in 2019 and a $2,993,665 European Innovation Council grant in 2021, supporting development of its robotic endovascular technology. It received non-equity assistance from MedTech Innovator on Jun 6, 2023 and then closed a $6,603,806 seed round led by Practica Capital on Dec 21, 2023. The funding history totals $9,654,313 across four recorded rounds, including grants and assistance. Product development has since moved through several inflection points: remote clinical demonstrations were highlighted in November 2025, CE marking was announced on May 22, 2026, and real-world European clinical use was described on Jul 23, 2026. On Aug 25, 2026, Sentante announced commercial rollout in vascular surgery and interventional radiology. The company has five identified current positions and is hiring for medical robotics roles, suggesting a small but expanding operating base. The next measurable indicators will be clinical utilization, hospital contracts, regulatory expansion, and conversion of procedural data into validated AI functionality.